case_images: PMC8646866_01
case_images: Changes on CT scans during treatment.
case_images: OTT-14-5363-g0001.jpg
case_images: PMC8646866_01_OTT-14-5363-g0001.jpg
case_images: f0001
case_images: The serum antigen-125 (CA-125) was 326.4 U/mL, and the abdominal enhanced CT (Figure 1A) showed an enlarged uterus, irregular soft tissue-like mass on the left posterior, and multiple nodules and masses in the peritoneum and omentum on both sides. CT scan revealed a significant reduction of pelvic mass (Figure 1B) and achieved partial remission (SD) according to RECIST 1.1. Considering that the patient cannot continue to afford avastin, medical insurance cannot be reimbursed in our country. However, the CT scan proved PD again and the therapy was unsuccessful (Figure 1C). Response evaluations after every two months during 10 cycles of treatment showed stable disease SD (Figure 1D).
case_images: H&E staining with surgical specimens of the patient.
case_images: OTT-14-5363-g0002.jpg
case_images: PMC8646866_01_OTT-14-5363-g0002.jpg
case_images: f0002
case_images: Laparoscopic biopsy was performed and the histopathology confirmed poorly differentiated adenocarcinoma originating from the ovary (Figure 2).
case_images: CA-125 levels change during treatment. After gefitinib maintenance treatment started in May 2018, the level of CA-125 remained stable at about 50 U/mL In October 2019, the CA-125 increased to 67.2U/mL. Endostar combined with apatinib treatment started in November 2019, and the CA-125 level was maintained within 50 U/mL again and entered a more stable state.
case_images: OTT-14-5363-g0003.jpg
case_images: PMC8646866_01_OTT-14-5363-g0003.jpg
case_images: f0003
case_images: During the treatment, CT and CA-125 (Figure 3) were reviewed every 2 months.